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In early fetal development, the testis secretes – independent of pituitary gonadotropins –
androgens and anti-Müllerian hormone (AMH) that are essential for male sex differentiation.
In the second half of fetal life, the hypothalamic–pituitary axis gains control of testicular
hormone secretion. Follicle-stimulating hormone (FSH) controls Sertoli cell proliferation,
responsible for testis volume increase and AMH and inhibin B secretion, whereas luteiniz-
ing hormone (LH) regulates Leydig cell androgen and INSL3 secretion, involved in the
growth and trophism of male external genitalia and in testis descent.This differential regu-
lation of testicular function between early and late fetal periods underlies the distinct clinical
presentations of fetal-onset hypogonadism in the newborn male: primary hypogonadism
results in ambiguous or female genitalia when early fetal-onset, whereas it becomes clini-
cally undistinguishable from central hypogonadism when established later in fetal life. The
assessment of the hypothalamic–pituitary–gonadal axis in male has classically relied on
the measurement of gonadotropin and testosterone levels in serum. These hormone lev-
els normally decline 3–6 months after birth, thus constraining the clinical evaluation window
for diagnosing male hypogonadism. The advent of new markers of gonadal function has
spread this clinical window beyond the first 6 months of life. In this review, we discuss the
advantages and limitations of old and new markers used for the functional assessment of
the hypothalamic–pituitary–testicular axis in boys suspected of fetal-onset hypogonadism.
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The concept of male hypogonadism is usually associated with
the adult patient, and rarely thought of as a condition in the
prepubertal boy. Furthermore, male hypogonadism is most fre-
quently equated to hypoandrogenism. Androgens are the dean
of testicular hormones, and the normal testis produces very lit-
tle or no testosterone during most of infancy and childhood.
It is therefore easy to understand why the term hypogonadism
is almost absent from the pediatrician’s terminology. However,
many hypogonadal states in the male bear their origin in fetal
life. With the advent of direct markers of Sertoli cell function,
hypogonadism can be identified in boys beyond the early post-
natal critical window of pituitary–gonadal activation (1) – called
“mini-puberty” by some authors – and before pubertal age. In this
review, we address the diagnostic approaches of fetal-onset male
hypogonadism based on the physiology and pathophysiology of
the hypothalamic–pituitary–testicular axis ontogeny.
ONTOGENY OF THE
HYPOTHALAMIC–PITUITARY–TESTICULAR AXIS
FETAL LIFE: THE FIRST VERSUS THE SECOND AND THIRD TRIMESTERS
The gonadotropin-releasing hormone (GnRH) neurons derive
from cells present in the nasal placode in the sixth fetal week
(2), which migrate together with olfactory axons and blood ves-
sels through the cribriform plate and arrive in the developing
forebrain in the 9th–10th weeks. Several genes are involved in the
development and migration of GnRH neurons, including KAL1,
FGF8, FGFR1, PROK2, PROKR2, CHD7, WDR11, and NELF, and
in their homeostasis and function, including DAX1 (or NR0B1),
LEP, LEPR, KISS1, KISS1R, TAC3, TACR3, and GNRH1 [reviewed
in Ref. (3, 4)].
The pituitary gonadotropes develop in the Rathke’s pouch fol-
lowing a sequential differentiating pathway, which also includes
the other pituitary cell lineages, from the oral ectoderm ancestor.
Early genes, like SHH, GLI1, GLI2, LHX3, LHX4, PITX1, PITX2,
OTX2, and HESX1, are involved in the differentiation of all pitu-
itary cell lineages, whereas TBX19 (or TPIT ), GATA2, and SF1 (or
NR5A1) are more specifically related to the gonadotrope lineage
[reviewed in Ref. (5)]. Fully functional gonadotropes are present
in the fetal male pituitary and secrete luteinizing hormone (LH)
from week 12 and Follicle-stimulating hormone (FSH) from week
14 (6). Circulating levels of both gonadotropins increase to attain
peak levels by weeks 20–25 and then decrease toward term (7–9).
The testes differentiate from the adreno-gonadal primordium
by the seventh week of gestation. Interestingly, Sertoli cells actively
secrete anti-Müllerian hormone (AMH), involved in the regres-
sion of the uterine anlage during the eighth and ninth weeks, i.e.,
before exposure to FSH. In fact, basal AMH expression is triggered
by SOX9 and enhanced by SF1, GATA4, and WT1 independent of
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FSH [reviewed in Ref. (10)]. Afterward, FSH increases testicular
AMH output by inducing Sertoli cell proliferation and AMH tran-
scription following the classic FSH receptor transduction pathway
involving protein kinase A and cyclic AMP (10, 11). Sertoli cells
also secrete inhibin B, which is present at high levels in the serum
of mid-term fetuses and only slightly lower by term (8, 9). Sertoli
cells are not directly regulated by androgens during fetal life since
they do not express the androgen receptor [reviewed in Ref. (12)].
Approximately 1 week later than Sertoli cells do, Leydig cells dif-
ferentiate in the interstitial tissue and secrete testosterone, respon-
sible for the differentiation of the male gonaduct, the prostate,
and the external genitalia, independently from fetal pituitary LH.
In fact, the major regulator of testosterone production during the
first trimester is chorionic gonadotropin (hCG), which circulates
at high levels in fetuses with a peak at 12–17 weeks subsequently
decreasing through term (7, 13). The relevance of fetal LH in Ley-
dig cell function becomes more evident during the second and
third trimesters. Both LH and hCG act on the same transmem-
brane receptor, the LHCG-R, present on the Leydig cell membrane
and inducing cell proliferation and differentiation as well as andro-
gen and insulin-like 3 (INSL3) synthesis and secretion. Male dif-
ferentiation of internal and external genitalia is completed in the
first trimester (Figure 1). Afterward, androgens induce the growth
of the phallus and the trophism of the scrotum, whereas both
androgens and INSL3 are important for testicular descent (14).
POST-NATAL LIFE: INFANCY, CHILDHOOD, AND PUBERTY
The decreasing trend in the whole hypothalamic–pituitary–
testicular axis activity is reflected in low perinatal levels of all
hormones (Figure 2) (9). Thereafter, an increase in circulating
levels is observed in the neonate already by the end of the first
week for gonadotropins, and from the second to fourth weeks for
AMH, inhibin B, and testosterone (15, 16). It should be noted for
testosterone that serum samples must be extracted to avoid inter-
ferences that artificially overestimate results (Figure 2). LH drives
testosterone and INSL3 to peak levels during the third month;
thereafter, they all decline and attain very low or undetectable lev-
els after the sixth month (Figure 1) (16–18). Assays for INSL3 are
now commercially available, with sufficient sensitivity to be used
in patients during childhood (19), although an hCG test may be
needed.
On the other hand, FSH continues to induce Sertoli cell pro-
liferation resulting in a continuous increase in testis volume.
Androgens may also exert a proliferative effect on Sertoli cells
(20), but the effect should be indirect since the androgen recep-
tor is still not expressed in Sertoli cells during early infancy
[reviewed in Ref. (12)]. It should be noted that the absolute
volume increment described in this period of life is modest
(<1.5 mL) and cannot be clinically evidenced by palpation (21).
AMH and inhibin B secretion is also enhanced: the levels of
both hormones increase progressively through infancy (Figure 1)
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FIGURE 1 | Schematic representation of the pituitary–testicular axis hormone levels and of sexual differentiation and development of male internal
and external genitalia. WD diff., Wolffian duct differentiation; MD regr., Müllerian duct regression; EG diff., differentiation of the external genitalia.
Frontiers in Endocrinology | Pediatric Endocrinology May 2014 | Volume 5 | Article 51 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Grinspon et al. Fetal-onset male hypogonadism
FIGURE 2 | Serum levels of gonadotropins and testicular hormones in male newborns. Data obtained from Ref. (15).
(15, 22, 23). The increase observed during the first months of
life may be linked to the marked proliferation of Sertoli cells that
occurs after mid-gestation with a further increment after birth
(24), probably enhanced by the post-natal gonadotrophic surge.
Serum inhibin B levels are as high as those observed in puber-
tal boys during the first 6 months of age; thereafter, a progressive
fall occurs until the age of 4–6 years, but serum concentrations
remain considerable, since they are above the lowest limit of
normal adult range (23), and can be readily detected with the
commercially available new generation assays (25). Serum AMH
peaks during the second year and then remains fairly stable
during childhood (22, 26). Altogether, these data clearly indi-
cate that Sertoli cells are functionally active during infancy and
childhood.
Testosterone and inhibin B are the most relevant physiological
factors involved in gonadotropin negative feedback in the adult. A
possible role for inhibin B in FSH negative feedback before puberty
is still a matter of debate. Higher FSH than LH levels observed in
boys with no functional gonadal tissue (27–29), the inverse corre-
lation between FSH and inhibin B levels observed in cryptorchid
boys (30), and the suppression of FSH secretion observed in pre-
pubertal patients with Sertoli cell neoplastic proliferations and
increased inhibin B (31) support the hypothesis of the active role
that inhibin B has in regulating FSH. However, the decrease in
LH and FSH levels during normal male childhood is not fully
dependent on these testicular hormones, since it also occurs in a
considerable proportion of boys with gonadal dysgenesis (27) or
anorchia (Figure 3) (29).
A progressive increase in gonadotropin pulse amplitude and
frequency occurring between 9 and 14 years of age triggers testic-
ular pubertal maturation. LH induces Leydig cells androgen pro-
duction again: intratesticular testosterone concentration increases
and acts on Sertoli cells, which now express the androgen receptor.
Consequently, they acquire a mature phenotype characterized by
the development of the blood–testis barrier and a down-regulation
of AMH production [reviewed in Ref. (12)]. The rise in serum
testosterone occurs 1–2 years later (32, 33). Germ cells, hith-
erto limited to spermatogonia, enter meiosis and go through the
complete spermatogenic process giving rise to spermatozoa. Sper-
matogenic development is responsible for the remarkable increase
of testis volume during puberty. FSH and germ cells induce an
increase in inhibin B. Serum levels of inhibin B increase concomi-
tantly with testicular volume, and attains adult levels as early as
pubertal stage II (23, 34, 35). INSL3 secretion also increases during
puberty (36); in adult, the production and secretion of INSL3 is
maintained by the long-term trophic effect of LH on Leydig cell
structure and function and independent of the acute steroidogenic
effect of LH (16).
DEFINITION AND CLASSIFICATION OF CONGENITAL MALE
HYPOGONADISM
From the comprehension of the changes occurring in the normal
physiology of the pituitary–testicular axis during pre- and post-
natal life, it emerges clearly that male hypogonadism cannot be
limited to hypoandrogenism. The definition should be extended
to all situations characterized by a decreased testicular function,
as compared to what is expected for age, involving an impaired
hormone secretion by Leydig cells (androgens, INSL3) and/or Ser-
toli cells (AMH, inhibin B) and/or a disorder of spermatogenesis
(Table 1).
It should also be considered that the clinical manifestations of
male hypogonadism will vary according to: (a) the level of the
hypothalamic–pituitary–testicular axis primarily affected, (b) the
testicular cell population initially impaired, and (c) the period of
life when the condition is established (37).
LEVEL OF THE AXIS PRIMARILY AFFECTED: CENTRAL, PRIMARY, OR
COMBINED HYPOGONADISM
In central (or hypothalamic–pituitary) hypogonadism, testicular
failure is secondary to a disorder affecting the secretion of GnRH
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FIGURE 3 | Serum levels of gonadotropins in anorchid boys. Reproduced from Ref. (29), ©2012 Blackwell Publishing Ltd., with permission from Blackwell
Publishing Ltd., John Wiley and Sons.
Table 1 | Classification of fetal-onset male hypogonadism.
Whole gonadal
dysfunction
Cell-specific gonadal
dysfunction
PRIMARY HYPOGONADISM
First trimester Gonadal dysgenesis Leydig cells
LHCG-R mutation
Steroidogenic protein
defects
Sertoli cells
AMH mutation
Second – third
trimesters
Testicular regression
syndrome
Leydig cells
INSL3 mutation
Testicular torsion
Endocrine disruptors Sertoli cells
FSH-R mutation
CENTRAL HYPOGONADISM
Second – third
trimesters
Multiple pituitary hormone
deficiency
Leydig cells
LHβ-subunit gene
mutation
Neurokinin defects
Isolated hypogonadotropic
hypogonadism (IHH)
Sertoli cells
FSHβ-subunit gene
mutation
COMBINED HYPOGONADISM
First trimester DAX1 gene mutations None
Second – third
trimesters
Prader–Willi syndrome None
or gonadotropins. It is usually characterized by an impaired pro-
duction of both LH and FSH, and thus called hypogonadotropic
hypogonadism; however, as discussed later, this nomenclature
is not always applicable, and some cases of central hypogo-
nadism may present with normal or even increased levels of one
gonadotropin.
In primary hypogonadism, the testis is the primarily affected
organ. This may lead to an impaired production of testicu-
lar hormones and a disruption of the negative feedback to the
hypothalamic–gonadotrope axis, which results in an elevation of
FSH and/or LH. In adult endocrinology, primary hypogonadism is
usually identified as hypergonadotropic; however, as discussed in
the previous section, during childhood, primary hypogonadism –
or even agonadism – may present with normal gonadotropin
levels (27–29).
In certain disorders, both the hypothalamic–gonadotrope axis
and the testis are affected concomitantly, e.g., in DAX1 muta-
tions or in oncologic patients exposed to cranial radiotherapy
and chemotherapy. These “dual” conditions are characterized by
a lack of gonadotropin elevation during puberty or adulthood in
spite of the low testicular secretion of androgens and/or inhibin B
[reviewed in Ref. (37)].
WHOLE TESTICULAR VERSUS SPERMATOGENIC, LEYDIG CELL-SPECIFIC
OR SERTOLI CELL-SPECIFIC FAILURE
Whole testicular failure or hypogonadism reflects the concomi-
tant impairment of all testicular cell populations. On the contrary,
the disorder may primarily involve only one testicular cell pop-
ulation; for instance, spermatogenic-specific failure results from
Yq chromosome deletions, steroidogenic failure from defects in
LH, its receptor or steroidogenic enzymes, and Sertoli cell-specific
hypogonadism from defects in FSH or its receptor or in the AMH
gene, as we discuss more in detail below.
ONSET OF MALE HYPOGONADISM: FETAL VERSUS POST-NATAL LIFE
Male hypogonadism can be congenital, i.e., fetal-onset hypogo-
nadism, or result from a condition acquired during post-natal
life. The clinical presentation depends on the period of life in
which testicular failure is established. In adulthood, androgen defi-
ciency leads to decreased libido, impotence, fatigue, loss of bone
and muscle mass, increased fat mass and metabolic disorders, and
spermatogenic failure results in oligo- or azoospermia. At puber-
tal age, male hypogonadism results in the absence or the arrest
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of pubertal development. Because the hypothalamic–pituitary–
steroidogenic function is normally low during childhood – as
explained above – male hypogonadism remains clinically unap-
parent when established in this period of life unless suspected and
actively sought for by measuring serum AMH or inhibin B in basal
conditions, or testosterone or INSL3 after stimulation with hCG
[reviewed in Ref. (37)]. Fetal-onset hypogonadism may lead to
a variety of clinical presentations, which are discussed in detail
below.
PATHOPHYSIOLOGY OF FETAL-ONSET MALE
HYPOGONADISM
The clinical consequences of fetal-onset male hypogonadism can
be deduced from the understanding of the normal ontogeny of
the male reproductive axis during fetal life described above. When
established in the first trimester, the lack or insufficient levels of
testis hormones during the critical window of male sex differen-
tiation (weeks 8–13) lead to disorders of sex development (DSD)
presenting with female or ambiguous genitalia. Because Leydig
cell androgen production is essentially under placental hCG – not
fetal LH – control in the first trimester, central hypogonadism
does not result in DSD. Primary hypogonadism established in
the second half of gestation and central hypogonadism lead to a
decreased number of Sertoli cells and also to an impaired testicu-
lar output of androgens and INSL3. The clinical consequences are
microorchidism, micropenis, and cryptorchidism.
PRIMARY HYPOGONADISM ESTABLISHED IN THE FIRST TRIMESTER
Whole testicular dysfunction: gonadal dysgenesis
Gonadal dysgenesis may result from chromosomal aberrations
or mutations affecting genes controlling testicular differentiation
(Table 2). Chromosome aberrations involving the short arm of
the Y chromosome cause gonadal dysgenesis affecting all cell pop-
ulations. Similarly, deletions of the short arm of chromosome
9 – where DMRT1 and DMRT2 map (38) – and duplications of
Xp21.3-p21.2 – where DAX1 gene maps (39) and of 1p31-p35 –
where WNT4 maps (40) – result in testicular dysgenesis. 46,XY
patients with mutations in SRY (41) orMAMLD1 (42) also present
with gonadal dysgenesis. Mutations in other genes associate tes-
ticular dysgenesis with dysfunctions of other organs (Table 2).
SF1 mutations may associate gonadal dysgenesis with adrenal fail-
ure (43), yet isolated testicular dysfunction can be observed (44).
Mutations in WT1 result in gonadal dysgenesis associated with
degenerative renal disease, resulting in Denys–Drash syndrome
or in Frasier syndrome (45). Haploinsufficiency of SOX9 leads
to a polymalformative syndrome including gonadal dysgenesis,
bowing and angulation of long bones (known as campomelic dys-
plasia), hip dislocation, hypoplastic scapula, small thoracic cage,
macrocephaly, facial dysmorphism, and cardiac and renal defects
(40, 46). Homozygous mutations of DHH gene result in the asso-
ciation of gonadal dysgenesis and minifascicular neuropathy (47,
48). Mutations in XH2 gene cause the ATRX syndrome, character-
ized byα-thalassemia, mental retardation, facial dysmorphism and
gonadal dysgenesis (49). Recently, MAP3K1 mutations have been
identified as another cause of partial or complete gonadal dysgen-
esis (50). Finally, mutations inTSPYL1 have been found in patients
with gonadal dysgenesis and sudden death (51). However, the
vast majority of dysgenetic DSD cases remain unexplained, which
suggests that several other gene defects may be the underlying
cause.
Exposure to environmental disruptors in utero has also been
implicated as the underlying cause for interlinked reproductive
disorders like cryptorchidism, hypospadias, infertility and tes-
ticular cancer, which seem to show an increasing trend. This
association is known as the testicular dysgenesis syndrome (52).
When the gonadal dysgenesis is complete, internal and external
genitalia differentiate along the female pathway since the streak
gonads do not secrete any androgens or AMH. These 46,XY girls
are apparently normal and do not seek medical attention until
pubertal age when they present with absence of telarche and
menarche. Only in the case of contradiction between a karyotype
performed during gestation and the lack of virilization, does the
case present to the specialist immediately after birth.
In partial forms of testicular dysgenesis, the degree of undervir-
ilization depends on the amount of functional gonadal tissue the
patient has. The external genitalia may be more or less ambigu-
ous, testes do not descend and Wolffian derivatives are more or
less atrophic as signs of insufficient androgen secretion, reflect-
ing Leydig cell dysfunction. The persistence of müllerian deriv-
atives reflects defective AMH production as a sign of Sertoli cell
dysfunction.
In both complete and partial forms, the androgen and inhibin
B feedback mechanisms are insufficient and the gonadotrope
secretion of gonadotropin is exaggerated.
Leydig cell-specific dysfunction: isolated fetal hypoandrogenism
When only Leydig cell development and/or function are primarily
disturbed in the first trimester of fetal life, insufficient androgen
production results in undervirilisation and cryptorchidism. On
the contrary, Sertoli cells are normally active and secrete AMH
which induces full regression of Müllerian ducts. Therefore, this
apparently normal girl has no uterus and a short blind-end vagina.
Similar to complete gonadal dysgenesis, these patients seek medical
attention at pubertal age because of the absence of telarche and
primary amenorrhea. In the cases of a partial defect, androgen
secretion is insufficient to virilize the fetus adequately: the new-
born has ambiguous external genitalia and hypotrophic Wolffian
duct derivatives. The degree of virilization is commensurate with
the residual steroidogenic activity of the gonads. The gonadotrope
secretes excessive gonadotropins with an increased LH:FSH ratio,
because FSH is negatively regulated by inhibin B.
Leydig cell aplasia is a rare form of isolated fetal hypoandro-
genism leading to a DSD due to inactivating mutations of the
LHCG-R (Table 3) [reviewed in Ref. (53)]. Defective androgen
production by the testis can also result from mutations in one of
the five enzymatic activities necessary for the synthesis of testos-
terone from cholesterol (Table 3). Three of these are common to
adrenal and gonadal steroidogenesis: cholesterol side-chain cleav-
age (P450scc), 3β-hydroxysteroid dehydrogenase (3β-HSD), and
17α-hydroxylase (P450c17). A deficiency in any of these in 46,XY
individuals results in testicular hypoandrogenism leading to gen-
ital ambiguity and adrenal insufficiency leading to congenital
adrenal hyperplasia. Two steroidogenic steps – 17,20-lyase (activ-
ity contained in P450c17) and 17β-hydroxysteroid dehydrogenase
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Table 2 | Clinical features in male patients with fetal-onset primary hypogonadism with whole gonadal dysfunction.
Affected chromosome Gene OMIM Associated clinical features
9p24 deletion DMRT1 and DMRT2 #154230 Dysgenetic DSD
Mental retardation, microcephaly, facial malformations, short stature
Digestive or bronchial malformations
Xp21 duplication DAX1=NR0B1 and other genes #300018 Dysgenetic DSD
1p31-p35 duplication WNT4 and other genes *603490 Dysgenetic DSD
Yp11.31 SRY *48000 Dysgenetic DSD
Xq28 MAMLD1 *300120 Dysgenetic DSD
9q33.3 SF1=NR5A1 +184757 Dysgenetic DSD
Adrenal insufficiency
11p13 WT1 #136680 Dysgenetic DSD
#194072 Renal dysgenesis/tumor (Denys–Drash, Frasier and WAGR syndromes)
#194080
17q24.3 SOX9 #114290 Dysgenetic DSD
Campomelic dysplasia
12q13.12 DHH #233420 Dysgenetic DSD
Minifascicular neuropathy
Xq21.1 ATRX =XH2 #301040 Dysgenetic DSD
Mental retardation, α-thalassemia
5q11.2 MAP3K1 #613762 Dysgenetic DSD
6q22.1 TSPYL1 #608800 Dysgenetic DSD
Sudden infant death
DSD, disorder of sex development; OMIM, Online Mendelian Inheritance in Man locus, gene and phenotype numbers (http:// www.ncbi.nlm.nih.gov/ omim).
(17β-HSD) – are required only for gonadal steroidogenesis; there-
fore, their defects result only in hypovirilization without adrenal
insufficiency [reviewed in Ref. (53)].
Sertoli cell-specific dysfunction: AMH deficiency
The persistent Müllerian duct syndrome (PMDS) is a rare form
of DSD characterized by persistence of Müllerian derivatives in
otherwise normally virilized 46,XY individuals. Regression of
Müllerian ducts normally occurs between 8 and 10 weeks of fetal
development, under the influence of AMH produced by fetal Ser-
toli cells. If active AMH is not produced, owing to AMH gene
mutations, Müllerian ducts develop into uterus, fallopian tubes,
and upper vagina notwithstanding normal virilization of external
genitalia and urogenital sinus. PMDS can also be consecutive to
mutations of the AMH receptor type II gene (AMHR2), but in this
case testicular function is normal [reviewed in Ref. (54)]. PMDS
should not be considered in patients with defects in the virilization
of external genitalia. Gonadotrope activity is not affected during
fetal life.
PRIMARY HYPOGONADISM ESTABLISHED IN THE SECOND AND THIRD
TRIMESTERS
Whole testicular dysfunction: testicular regression syndrome
The existence of fully virilized external genitalia, i.e., completely
fused scrotum and a urethral opening at the tip of the penis, is
indicative of the existence of functional testes in the first trimester
of gestation. However, the gonads may undergo regression (van-
ishing testes) due to torsion of the spermatic cord or to other
unknown situations, resulting in a deficient or completely absent
exposure to testicular hormones until the end of fetal life. The
hypoandrogenism leads to scrotal hypotrophy and micropenis.
Androgen and inhibin B insufficiency results in an exaggerated
gonadotrope activity.
Leydig cell-specific dysfunction: INSL3 deficiency
Mutations in INSL3 lead to a rare form of Leydig cell-specific
dysfunction without hypoandrogenism. Newborns are normally
virilized but present with cryptorchidism, reflecting the defect in
testicular descent [reviewed in Ref. (55)]. Because INSL3 has no
effect on the gonadotrope, LH and FSH secretion are not disturbed
in these individuals during fetal life.
Sertoli cell-specific dysfunction: FSH receptor mutations
As already discussed, Sertoli cell differentiation in early fetal life is
not dependent on FSH; therefore, male fetuses with FSH receptor
mutations secrete sufficient amounts of AMH to induce Müllerian
duct regression. On the contrary, since FSH is an important Ser-
toli cell mitogen, FSH-R mutations lead to Sertoli cell hypoplasia
and small testes. Adults have low sperm count, low inhibin B, and
moderately elevated FSH (56).
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Table 3 | Clinical features in male patients with fetal-onset primary hypogonadism with Leydig cell-specific (steroidogenic) dysfunction.
Gene Protein OMIM Hormone levels Associated clinical features
LHCG-R LH/CG receptor #238320 ↓↓ All steroids None
STAR StAR #201710 ↓↓ All steroids Lipoid congenital adrenal hyperplasia
CYP11A1 P450scc #613743 ↓↓ All steroids Adrenal insufficiency
CYP17A1 P450c17 (17α-hydroxylase activity) #202110 ↑ Pregnenolone Adrenal insufficiency
↑ Progesterone Hypertension
CYP17A1 P450c17 (17,20-lyase activity) #202110 ↑ 17OH-pregnenolone Adrenal insufficiency
↑ 17OH-progesterone
↑ Pregnenolone
↑ Progesterone
POR P450 oxidoreductase #613571 ↑ Progesterone Antley–Bixler syndrome
↑ 17OH-progesterone
HSD3B2 3β-HSD type 2 #201810 ↑ DHEA Adrenal insufficiency
↑ 17OH-pregnenolone
↑ Pregnenolone
HSD17B3 17β-HSD type 3 #264300 ↑ Androstenedione None
↑ DHEA
↑ 17OH-progesterone
↑ 17OH-pregnenolone
OMIM, Online Mendelian Inheritance in Man locus, gene and phenotype numbers (http:// www.ncbi.nlm.nih.gov/ omim).
CENTRAL HYPOGONADISM ESTABLISHED IN THE SECOND AND THIRD
TRIMESTERS
Whole testicular dysfunction: hypogonadotropic hypogonadism
As already discussed, deficient LH and FSH production by the fetal
pituitary has no effect on sexual differentiation occurring in the
ninth to thirteenth weeks of gestation, but do impact on genital
development dependent on testicular function in the second and
third trimesters of fetal life. Gonadotropin deficiency may result
from an impaired differentiation of the gonadotrope in the con-
text of a defective development of the pituitary primordium, and
is therefore associated with multiple pituitary hormone deficiency.
Alternatively, the defect may be restricted to the gonadotrope axis
as a consequence of an impaired development, migration or func-
tion of the GnRH neurons, or of an impaired function of the
gonadotrope. The lack of gonadotropin stimulus in this period of
fetal development may result in small testes due to FSH deficiency,
micropenis reflecting hypoandrogenism due to LH deficiency, and
cryptorchidism as a sign of androgen and INSL3 insufficiency
secondary to LH deficiency.
Multiple pituitary hormone deficiency. Congenital hypopitu-
itarism occurs in approximately 1:4,000–1:10,000 newborns, with
a 7:3 male-to-female ratio (57), and involves multiple pituitary
cell lineages in approximately 80% of the cases. Mutations in genes
involved in early pituitary differentiation and development usually
result in multiple pituitary hormone deficiency including hypog-
onadotropic hypogonadism, usually due to pituitary hypoplasia.
Although variable, there are a few clinical signs that may help in
the identification of the underlying cause (Table 4) [reviewed in
Ref. (58, 59)]. For instance, the association of congenital multiple
pituitary hormone deficiency with septo-optic dysplasia (midline
neural defects and optic nerve hypoplasia) has been observed
in patients with mutations in HESX1, SOX2 and SOX3. Mid-
line defects, coloboma and polydactyly are also present in HESX1
patients, anophthalmia or microphthalmia and esophageal atresia
in SOX2 cases, and X-linked mental retardation in SOX3 muta-
tions. LHX3 defects are present in patients with rigid and short
cervical spine; LHX4 mutations can be found in individuals with
abnormalities in the central skull base;GLI2 in patients with holo-
prosencephaly; PITX2 in patients with Axenfeld–Rieger syndrome
(anomalies of anterior eye chamber, dental hypoplasia, craniofa-
cial dysmorphism, and protuberant umbilicus); SIX6 in patients
with absent optic chiasm and brain cortical atrophy, and OTX2 in
patients with microphthalmia. Defects in late development factors,
like PROP1 are present in non-syndromic patients with multi-
ple pituitary hormone deficiencies. Currently, only <15% of the
etiologies of congenital hypopituitarism have been identified (60).
Isolated hypogonadotropic hypogonadism. Congenital isolated
central hypogonadism can present as the only manifestation of
the disorder (normosmic hypogonadotropic hypogonadism), or
be associated with partial or complete loss of olfaction (Kallmann
syndrome or anosmic hypogonadotropic hypogonadism), usu-
ally associated with other anatomical and/or neurological defects
[reviewed in Ref. (61)].
Hyposmic/anosmic hypogonadotropic hypogonadism with or
without other syndromic features results from mutations in the
genes involved in the development and migration of the GnRH
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Table 4 | Clinical features in male patients with fetal-onset central hypogonadism associated with multiple pituitary hormone deficiency.
Gene OMIM Other pituitary lineages affected Associated clinical features
HESX1 #182230 Somatotrope Septo-optic dysplasia
Lactotrope Midline defects
Thyrotrope Coloboma
Corticotrope Polydactyly
SOX2 #206900 Somatotrope Septo-optic dysplasia
Anopthalmia/microphthalmia
Sensorineural defects
Esophageal atresia
SOX3 #312000 Somatotrope Septo-optic dysplasia
Thyrotrope
Corticotrope
LHX3 #221750 Somatotrope Rigid and short cervical spine
Lactotrope Limited head rotation
Thyrotrope
LHX4 #262700 Somatotrope Hindbrain defects
Thyrotrope Abnormality of central skull base
Corticotrope
GLI2 #610829 Somatotrope Holoprosencephaly
Lactotrope
Thyrotrope
Corticotrope
PITX2 #180500 Somatotrope Axenfeld–Rieger syndrome (anomalies of anterior eye chamber, dental
hypoplasia, craniofacial dysmorphism and protuberant umbilicus)Thyrotrope
SIX6 #212550 Somatotrope Anophthalmia
Brain cortical atrophy
Brachiootorenal syndrome
Oculoauriculovertebral spectrum
OTX2 #613986 Somatotrope Microphthalmia/anophthalmia
Thyrotrope Cleft palate
Corticotrope Developmental delay
PROP1 #262600 Somatotrope Intra- and extra-sellar cell mass, which may degenerate leading to empty
sella later in lifeThyrotrope
Corticotrope
OMIM, Online Mendelian Inheritance in Man locus, gene and phenotype numbers (http:// www.ncbi.nlm.nih.gov/ omim).
neurons from the olfactory placode to the hypothalamus [reviewed
in Ref. (61)]. The insufficient GnRH production is associated
with olfactory bulb hypoplasia or aplasia in magnetic resonance
imaging. Associated clinical manifestations may change accord-
ing to the defective gene: KAL1, FGF8 and its receptor FGFR1,
PROK2 and its receptor PROKR2,CHD7,NELF,HS6ST1,WDR11,
SEMA3A (Table 5) [reviewed in Ref. (4)].
Normosmic isolated hypogonadotropic hypogonadism is the
consequence of defects in genes involved in the regulation and
function of the GnRH neuron or the gonadotrope. Impaired
GnRH production may result from mutations in the GNRH1 gene
or from defective regulation of the GnRH neuron by kisspeptin,
neurokinin, or leptin signaling via their respective receptors.
Mutations in the GNRHR gene, encoding the GnRH receptor
present in the gonadotrope, are responsible for an impaired pitu-
itary response to GnRH. In all the cases, except for defects in
the neurokinin system, the secretion of both LH and FSH is
impaired.
Cell-specific dysfunction: dissociated hypogonadism
Isolated LH deficiency. Congenital isolated LH deficiency with
normal or high FSH production results from mutations in the
LHB gene encoding the β subunit of LH (62, 63), and from
defects in the neurokinin system responsible for the regulation
of GnRH pulses. Neurokinin is a neuropeptide encoded by TAC3,
which signals via the neurokinin receptor encoded by TACR3 (64,
65). Micropenis and cryptorchidism may be observed, as a con-
sequence of the fetal hypoandrogenism during the second and
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Table 5 | Associated clinical features in male patients with fetal-onset
isolated central hypogonadism due to defects in the migration of the
GnRH neuron.
Gene OMIM Associated clinical features
KAL1 #308700 Bimanual synkinesia, unilateral renal agenesis
Less frequently: palate defects (cleft lip/palate),
dental agenesis, ataxia, nystagmus, ear
anomalies, hearing loss, visual defects,
abnormal ocular movements
FGF8/
FGFR1
#612702
#147950
Cleft lip/palate, bone anomalies (syndactilia),
dental agenesis
Less frequently: hearing loss, bimanual
synkinesia, ear anomalies, midline facial defects,
choanal atresia, cardiac defects, coloboma
PROK2/
PROKR2
#610628
#244200
Sleep disorder, high-arched palate, bimanual
synkinesia, hearing loss, pectus excavatum,
hypodontia, obesity, nystagmus
CHD7 #612370 Coloboma, heart defects, choanal atresia,
retardation of growth, genital anomalies, and
ear abnormalities
NELF #614838 None
HS6ST1 #614880 Cleft lip/palate, clinodactyly
WDR11 #614858 No
SEMA3A #614897 No
OMIM, Online Mendelian Inheritance in Man locus, gene and phenotype
numbers (http:// www.ncbi.nlm.nih.gov/ omim).
third trimesters, but there is normal testes volume in the new-
born and child, because FSH levels are adequate. A mild form of
isolated LH deficiency is the underlying pathophysiology of the
“fertile eunuch” syndrome, characterized by the absence of signs
of hypoandrogenism until puberty, when eunuchoid proportions
become apparent in males with normal testis volume and sperm
production. Mutations in GNRHR (66) and LHB (67) genes have
been described.
Isolated FSH deficiency. Male fetuses with insufficient FSH may
develop small testes during the second and third trimesters owing
to Sertoli cell hypoplasia. External genitalia do not show signs of
hypoandrogenism since LH production is normal or elevated (68).
COMBINED OR DUAL (PRIMARY AND CENTRAL) HYPOGONADISM
DAX1 is a transcription factor encoded by NR0B1 mapping to
the short arm of the X chromosome. It has essential functions
at several levels of the pituitary–gonadal and adrenal axes. DAX1
mutations result in a disorder characterized by adrenal hypoplasia
and combined hypogonadism (Table 1). Testicular Sertoli and Ley-
dig cell function is primarily affected resulting in moderately low
hormone production; however, since the hypothalamic–pituitary
axis is also defective, the gonadotrope is unable to increase LH
and FSH production, despite the absence of an effective negative
feedback loop.
Prader–Willi syndrome is another form of combined cen-
tral and primary hypogonadism. This condition results from the
lack of the paternally inherited chromosome 15 region q11-q13;
this can be due to deletions in the paternal chromosome, to
maternal disomy of 15q11-q13, or to a defective imprinting that
silences the paternal chromosome 15. Several genes expressed
exclusively from the paternal chromosome are believed to be
involved in this syndrome (including MAGEL2, MKRN3, NDN,
SNURF-SNRPN , and the HBII genes), although their under-
lying mechanism is not well understood (69). Hypogonadism
is reflected in signs such as micropenis, cryptorchidism, scrotal
hypoplasia, and microorchidism (70). However, the pathophys-
iology seems to be heterogeneous, and hypogonadism may be
observed earlier or later in life, with a diverse participation of
the hypothalamic–pituitary axis (19, 71–74).
DIAGNOSTIC ASSESSMENT OF FETAL-ONSET MALE
HYPOGONADISM
The clinical and laboratory assessment of boys with suspected
hypogonadism shows a wide spectrum and varies according to
the etiology of the condition. Signs of hypoandrogenism are com-
mon to all; however, as already discussed, these signs will vary
according to the period of fetal life in which hypogonadism is
established. On the other hand, the evaluation of the other tes-
ticular hormones, and of any associated non-reproductive phe-
notype, may be extremely helpful in the diagnostic assessment of
these boys.
PATIENTS WITH AMBIGUOUS OR UNDERVIRILIZED EXTERNAL
GENITALIA
If fetal hypogonadism is the underlying cause for the existence of
a DSD presenting with ambiguous or insufficiently virilized geni-
talia (i.e., hypospadias, bifid scrotum), the condition can only be
due to primary gonadal failure. The need for a differential diagno-
sis between testicular dysgenesis (i.e., whole gonadal dysfunction)
and a specific steroidogenic failure emerges. A few clinical signs can
be helpful in certain cases: the existence of two palpable gonads
>1 mL is highly indicative of non-dysgenetic DSD (75), whereas
the association of syndromic phenotypes – like skeletal dysplasia,
macro/microcephaly, cardiac or renal defects, thalassemia, men-
tal retardation, or minifascicular neuropathy orientate to gonadal
dysgenesis (Table 2). Skeletal dysmorphisms may be present in
patients with POR deficiency associated with the Antley–Bixler
syndrome. Association with adrenal insufficiency is indicative of
a non-dysgenetic steroidogenic defect (StAR, P450scc, P450c17,
POR, 3β-HSD), although mutations in SF1 resulting in gonadal
dysgenesis are also a possible cause.
Results from hormonal laboratory assessment in the newborn
and infant should be interpreted according to reference values
for age. In DSD patients, this is particularly relevant in the first
month of life (Figure 2) (15), when patients are studied for diag-
nosis. During the first 3–6 months after birth, basal hormone level
determinations may be helpful (Figure 4). The existence of nor-
mal levels of testosterone, AMH, and inhibin B rule out testicular
dysfunction, and other etiologies of DSD should be sought (76,
77). When all testicular hormones are low and gonadotropins are
elevated, gonadal dysgenesis is most likely [reviewed in Ref. (77)].
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FIGURE 4 | A schematic guide for the interpretation of serum
hormone levels in patients with fetal-onset male hypogonadism. IHH,
isolated hypogonadotropic hypogonadism; Inh B, inhibin B; MPHD,
multiple pituitary hormone deficiency; Nx, normal. Levels are considered
as high, normal, or low as compared to the reference levels for newborns
or prepubertal boys.
Low testosterone (53) with normal or elevated AMH (78) is char-
acteristic of Leydig cell-specific hypogonadism. A prolonged hCG
test (six IM injections every other day) and an ACTH test are nec-
essary to distinguish between LHCG-R, StAR, and steroidogenic
enzyme defects (Table 3). Gonadotropin levels may be some-
what elevated in the first months of life but they are usually
normal during childhood in patients with steroidogenic defects
(53). This is another example where primary hypogonadism is
not hypergonadotropic in pediatric patients.
PATIENTS WITH MALE GENITALIA
The existence of normal male external genitalia rules out a fetal
primary hypogonadism established in the first trimester, except
for the rare form of Sertoli cell dysfunction due to AMH muta-
tions leading to PMDS (54). PMDS patients were most frequently
present with bilateral cryptorchidism; serum AMH is undetectable
but the other reproductive hormones are within the normal range
for age.
Fetal-onset central hypogonadism and primary hypogonadism
established in the second or third trimester have clinical signs of
hypoandrogenism as a common feature: small penis and unde-
scended gonads. Microorchidism can be indicative of insufficient
FSH stimulus – i.e., central hypogonadism – or of a testicu-
lar regression syndrome – i.e., a primary hypogonadism that
can progress to anorchism. Because the hypothalamic–pituitary–
testicular axis remains active for 3–6 months after birth (17,
18), this period represents a window of opportunity to establish
the diagnosis of hypogonadism (1). However, the diagnosis can
still be suspected and confirmed during the rest of infancy and
childhood.
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In some cases, the clinical presentation with cholestasis and/or
hypoglycemia in the newborn or failure to thrive in infants can
orientate the diagnosis to multiple pituitary hormone deficiency.
Associated malformations in cerebral and hypothalamic-pituitary
regions found on magnetic resonance imaging can be of further
help (Table 4). A familial history of anosmia/hyposmia is sugges-
tive of the diagnosis of isolated central hypogonadism,which could
be reinforced by some anatomical or neurodevelopmental features
in the infant or child (Table 5). Associated primary adrenal fail-
ure could orientate to adrenal hypoplasia congenital due to DAX1
mutations, whereas neonatal hypotonia and developmental delay
may be indicative of Prader–Willi syndrome.
In childhood, primary hypogonadism does not equate to
hypergonadotropic hypogonadism
The endocrine laboratory is necessary to certify the diagnosis
of male hypogonadism. Basal gonadotropins, testosterone, and
INSL3 are useful until the age of 3–6 months; thereafter dynamic
stimulation tests are necessary to assess them. On the contrary,
the Sertoli cell markers, AMH and inhibin B, are informative
all through infancy and childhood without the need for stimu-
lation tests. As discussed earlier, the occurrence of micropenis and
non-palpable gonads prompts the differential diagnosis between
central hypogonadism and testicular regression after the first
trimester (Figure 4). If the patient is <3–6 months old, low lev-
els of gonadotropins and Leydig and Sertoli cell hormones are
suggestive of central hypogonadism (16, 79, 80), whereas high
gonadotropins associated with low/undetectable testicular hor-
mones are diagnostic of primary hypogonadism. After the age
of 6 months, basal testosterone and INSL3 are no longer informa-
tive because they are normally low/undetectable during the rest of
infancy and childhood. Low gonadotropins also lose usefulness.
Undetectable AMH (81–83) and inhibin B (83, 84) are diagnos-
tic of anorchia. The elevated levels of LH and FSH observed in
these boys during the first years of life can subsequently decline
to normal levels; therefore, serum gonadotropins within the ref-
erence range for age may not be informative during childhood
(29). This is another clear example in pediatrics where primary
hypogonadism is not hypergonadotropic.
Central hypogonadism is not always hypogonadotropic
The presence of micropenis, cryptorchidism, and microorchidism
should prompt an early diagnosis of central hypogonadism, from
which two main benefits may derive: first is to orientate the
diagnosis of multiple pituitary hormone deficiency, favoring the
opportune hormone replacement treatment (thyroid hormone,
hydrocortisone, growth hormone). Second, as it has been pos-
tulated that the neonatal gonadotropic surge is physiologically
important for testicular activity later in puberty and adulthood
(85), early treatment with recombinant FSH and LH or hCG could
be beneficial (79, 80). This also applies to isolated central hypogo-
nadism. Analogously to the usefulness of testosterone and INSL3
to monitor Leydig cell response to LH/hCG (16), AMH (86) and
inhibin B (87) are excellent markers of Sertoli cell response to
FSH. In patients with a suspicion of central hypogonadism, AMH
and inhibin B levels are suggestive if low but do not rule out the
diagnosis if normal (88).
The hypoandrogenic states leading to micropenis and cryp-
torchidism – resulting from isolated LH deficiency due to muta-
tions in the LHβ subunit or in the neurokinin system – are
characterized by low LH and testosterone, but normal or elevated
FSH. Interestingly, this central form of hypogonadism can even be
hypergonadotropic, as observed in a young patient with delayed
puberty, who had a functionally inactive but immunoreactive
LH resulting in elevated serum levels associated with low testos-
terone (89).
Conversely, congenital isolated FSHβ deficiency, which presents
with microorchidism but normal penile size and scrotal testes,
has undetectable FSH and low inhibin B in adults with normal
androgen with high LH after puberty (89, 90). No reports exist in
childhood.
CONCLUDING REMARKS
Fetal hypogonadism of the first trimester is primary and results
in dysgenetic or cell-specific forms of DSD. In the second and
third trimesters, primary and central hypogonadism share signs
of hypoandrogenism and defective INSL secretion – i.e., micrope-
nis, hypoplastic scrotum and cryptorchidism – and of Sertoli cell
hypoplasia – i.e., microorchidism. In prepubertal patients, classi-
cal serum markers, like gonadotropins and testosterone,are helpful
essentially during the first 3–6 months of life. With the advent of
AMH and inhibin B, a biochemical diagnosis can also be envisaged
during the rest of childhood. Clinical findings may also help in the
diagnosis beyond early infancy. Finally, the pediatrician should not
expect elevated gonadotropin levels during childhood to foresee a
primary hypogonadism.
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